Swan Global Investments LLC Has $42,000 Stock Position in Cibus, Inc. (NASDAQ:CBUS)

Swan Global Investments LLC cut its holdings in shares of Cibus, Inc. (NASDAQ:CBUS) by 57.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 15,000 shares of the company’s stock after selling 20,123 shares during the quarter. Swan Global Investments LLC owned about 0.06% of Cibus worth $42,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. FMR LLC lifted its position in shares of Cibus by 16.9% during the 3rd quarter. FMR LLC now owns 3,913,279 shares of the company’s stock valued at $12,757,000 after acquiring an additional 566,328 shares during the period. State Street Corp increased its stake in shares of Cibus by 43.6% in the third quarter. State Street Corp now owns 307,262 shares of the company’s stock valued at $1,002,000 after buying an additional 93,236 shares during the period. Wellington Management Group LLP acquired a new stake in shares of Cibus in the third quarter valued at about $111,000. Raymond James Financial Inc. bought a new stake in shares of Cibus during the 4th quarter valued at about $89,000. Finally, Commonwealth Equity Services LLC bought a new stake in shares of Cibus during the 4th quarter valued at about $62,000. 33.81% of the stock is currently owned by institutional investors.

Cibus Price Performance

Shares of NASDAQ:CBUS opened at $2.05 on Friday. Cibus, Inc. has a 1 year low of $1.80 and a 1 year high of $23.18. The company has a market cap of $54.23 million, a PE ratio of -0.09 and a beta of 2.04. The stock’s 50-day moving average is $2.33 and its 200 day moving average is $3.33.

Cibus (NASDAQ:CBUS) last issued its quarterly earnings results on Thursday, March 20th. The company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.19). Cibus had a negative return on equity of 28.17% and a negative net margin of 10,724.78%. The company had revenue of $1.21 million during the quarter, compared to the consensus estimate of $1.13 million. Analysts expect that Cibus, Inc. will post -2.96 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on CBUS shares. Canaccord Genuity Group dropped their target price on Cibus from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Wednesday, January 22nd. HC Wainwright reissued a “buy” rating and issued a $25.00 target price on shares of Cibus in a research report on Friday.

Cibus Company Profile

Cibus, Inc, a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases.